SCHEMBL1620237

SCHEMBL1620237

C=CCc1cc(Br)cc(OC)c1O[Si](C(C)C)(C(C)C)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.40
ALOX15 P16050 2/20 0.40
POLB P06746 3/20 0.37
DHFR P00374 1/20 0.37
CCR3 P51677 1/20 0.36
ALDH1A1 P00352 7/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
GABRA1 P14867 2/20 0.35
GABRB2 P47870 2/20 0.35
ALOX5 P09917 2/20 0.35
CNR2 P34972 1/20 0.35
MAPT P10636 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1620100 0.81 ALOX15 (0.37) ALOX15POLBALDH1A1CYP1A2CYP2C19
SCHEMBL1620372 0.75 ALOX15 (0.36) CYP3A4ALOX15MAPTCYP1A2CYP2C9
SCHEMBL1620174 0.73 GAA (0.51) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL4981069 0.69 GABRA1 (0.55) ALOX15ALDH1A1PPARGPPARDPPARA
SCHEMBL4978848 0.69 PYCR1 (0.48) CYP3A4ALOX15POLBALDH1A1PPARG
SCHEMBL9155750 0.67 FFAR4 (0.37) CYP3A4ALOX15CCR3ALDH1A1PPARG
SCHEMBL9843615 0.67 ADRA2C (0.52) ALDH1A1MAPTCYP1A2TDP1KDM4E
SCHEMBL22501536 0.67 CYP3A4 (0.60) CYP3A4ALOX15POLBDHFRALDH1A1
SCHEMBL3212159 0.67 ALOX15 (0.44) CYP3A4ALOX15MAPTCYP1A2ALOX12
SCHEMBL29352981 0.67 CYP3A4 (0.60) CYP3A4ALOX15POLBDHFRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194046-B1 Triazolone derivative EISAI R&D MAN CO LTD (JP) 2012-05-09 EP disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
EP-2194046-A1 Triazolone derivative Eisai R&D Management Co., Ltd. (JP) 2010-06-09 EP disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190783-A1 TRIAZOLONE DERIVATIVES H1-0, H1-10, H1-2 CYP3A4 245/4885ALOX15 4635/4885POLB 1411/4885
US-20110112109-A1 TRIAZOLONE DERIVATIVES H1-10, H1-0, H1-2 CYP3A4 261/4885ALOX15 4625/4885POLB 1289/4885
US-20080015199-A1 Triazolone derivatives F3, F12, F2 CYP3A4 182/4885ALOX15 2986/4885POLB 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.